Scientist Develops Blood Test to Predict Chances of Dementia

After Alzheimer's, frontal lobe dementia (FTD) is the form of dementia that occurs most frequently in patients younger than 65. In FTD, the disease process starts in the frontal lobe where large numbers of brain cells begin to die off.

The frontal lobe is the foremost part of the brain and constitutes about 30% of the brain. It’s involved in regulating behavior, movement and mood, and it’s responsible for cognitive functions such as language.

The first clinical signs of FTD are changes in behavior and personality, and then, in a later stage of the disease, the loss of memory functions.

Previous research has shown that there is a genetic defect in chromosome 17 in a large percentage of the families with FTD. There are two genes in chromosome 17 that, if a defect occurs, cause a hereditable form of FTD.

In 1998, defects were found in the gene for the tau protein, a substance that appears in the protein clots in the brains of FTD and Alzheimer's patients. In 2006, researchers discovered hereditable defects in the gene for the progranulin protein. They predicted that people with these hereditable defects produce only half of the normal amount of progranulin.

This has been confirmed by the research team, who have shown that a shortage of this growth factor leads to the dying off of brain cells in the frontal lobe and in this way causes FTD. New results indicate that progranulin also plays a role in the death of brain cells in other diseases of the brain, such as Alzheimer's and Amyotrophic Lateral Sclerosis.

On the basis of their research, Kristel Sleegers, a scientist from the research team, has developed a test for measuring the quantity of progranulin in the blood in a simple way. This test enables one to determine whether someone has an increased risk of FTD due to a shortage of progranulin long before symptoms appear.

The blood test can be used on a large scale and is much more simple and user-friendly than the current genetic tests. This finding also offers prospects for the early detection of FTD caused by a shortage of progranulin.

Further scientific research is needed to determine how a shortage of progranulin can be restored to normal.

Related Articles

Nutrient Mix Shows Promise in Improving Memory in Alzheimer's Disease

In the early stages of Alzheimer's disease, patients typically suffer a major loss of the brain connections necessary for memory and information processing. Now, a

Researcher Identifies Key Contributor in Development of Alzheimer's

Walter J. Lukiw, PhD, Associate Professor of Neuroscience and Ophthalmology at Louisiana State University Health Sciences Center in New Orleans, is the lead

Tests May Predict Driving Safety in People with Alzheimer's

There might soon be certain cognitive tests to help determine whether a person with Alzheimer's can safely get behind the wheel. "The number of people with

Gene Identified That Appears to Increase Risk of Alzheimer's Disease

Researchers have identified a gene that appears to increase a person's risk of developing late-onset Alzheimer's disease, the most common type of Alzheimer's